Summary Southern Guangxi, China has one of the highest incidences of hepatocellular carcinoma (HCC) in the world. Serum samples collected from subjects of an earlier case-control study (39 cases, 41 controls) and from a random sampling of a residential male cohort (n = 100) were tested for antibodies for the hepatitis C virus (anti-HCV) using ELISA version 2.0 with confirmation by RIBA version 2.0. Only one of 141 (0.7%, upper 95% confidence limit, 3.2%) control subjects and none of 39 (upper 95% confidence limit, 6.07%) HCC cases tested positive for anti-HCV. Our results indicate that hepatitis C infection is not an important environmental determinant of HCC risk in this hyperendemic region.
Hepatocellular carcinoma (HCC) varies widely in incidence worldwide. It is a relatively rare malignancy in the United States and most of western Europe, but is one of the commonest cancers in large parts of Asia and sub-Saharan Africa (Parkin et al., 1992) . In the People's Republic of China, liver cancer represents the third and fourth commonest causes of cancer death in men and women respectively (Li et al., 1979) . There is considerable geographical variation in HCC incidence within China, the high-risk regions are mostly in the southeastern corner of the country with southern Guangxi exhibiting one of the highest rates of HCC incidence in the world. In Fusui County in southern Guangxi, the standardised incidence rate of liver cancer among men is 120 per 100 000 population per year, which is 50 times higher than the comparable rate in US whites (Yeh et al., 1989; Parkin et al., 1992) .
Previously, we have shown that chronic infection with the hepatitis B (HB) virus is a primary risk factor for HCC in southern Guangxi. In a cohort study of young and middleaged men in five rural communities in southern Guangxi, we demonstrated that approximately one-quarter of the male population are chronic HB carriers, and that liver cancer is responsible for half of all deaths in adult men. Over 90% of subsequent HCC cases were tested positive for hepatitis B surface antigen (HBsAg) at recruitment, and the incidence of HCC among HB carriers was close to 1 % per year (Yeh et al., 1989) . There was also strong suggestive evidence that dietary aflatoxin, primarily through ingestion of mouldy corn, is an important cofactor in liver cancer development in Guangxi. We observed a 3.5-fold variation in HCC incidence between the five rural communities which constituted our cohort, although these subpopulations displayed comparable prevalence of HBsAg positivity. However, repeated dietary and food surveys have established that these communities differed in their mean exposure levels to aflatoxin B1, from a high of 51.8 mg per person per year to a low of 0.3 mg per person per year. When HCC rates in these communities were plotted against their mean load of aflatoxin Bi, an almost perfectly linear relationship was noted (Yeh et al., 1989 (Yeh et al., 1985) and the previously described cohort (Yeh et al., 1989) , both of which were conducted in southern Guangxi.
Materials and methods
Case -control study The design of this study has been published (Yeh et al., 1985) . Briefly, cases were HCC patients at the clinic/ward of the Affiliated Hospital of the Guangxi Medical College in the city of Nanning. Controls were other clinic/ward patients whose present illnesses were not hepatitis or other liver diseases. Controls were individually matched to the cases by age (within 5 years), sex and clinic vs ward status. All subjects were recruited during 1982. The mean ages of the cases and controls were 44.3 and 44.5 years respectively. The original data set consisted of 50 cases (47 men, 3 women) and 50 controls. Owing to inadequate serum, the present analysis was restricted to 39 cases and 41 controls.
Blood specimens from all cases and controls were processed shortly after collection and stored at -20°C until analysis [for HBsAg, antibodies to the hepatitis B core antigen (anti-HBc) and antibodies to the hepatitis B surface antigen (anti-HBs)] in Los Angeles in 1983. Except for that single thaw, these specimens had been continuously frozen at -20°C until the present analysis.
Cohort study The design of this study has been published (Yeh et al., 1989 (1995) , and the three studies that used Chinese reagents suggests a higher proportion of false-positives in the latter assays. In Taiwan, a series of studies based on the patient population in the Kaohsiung Medical College Hospital (situated in southern Taiwan) has reported anti-HCV positivity rates of 20 to 39% in HCC patients, most of whom were males (Jeng et al., 1991; Chuang et al., 1992; Tsai et al., 1994a,b,c) . All five studies employed either the first- (Jeng et al., 1991; Chuang et al., 1992) or second-generation Abbott assay for anti-HCV testing; none used an independent confirmatory test on positive samples. There was no appreciable difference in anti-HCV rates between the two studies using the first-generation kit and the latter three studies using the second-generation kit. The overall rate of anti-HCV positivity in HCC cases pooled from the five studies was 30%. Two other studies conducted in central/ northern Taiwan (also primarily in men) reported lower rates of anti-HCV among HCC cases (both at around 13%) (Lee et al., 1992; Chang et al., 1994) . The above studies (Jeng et al., 1991; Chuang et al., 1992; Tsai et al., 1994a,b,c; Chang et al., 1994) were fairly consistent in their reported rates of anti-HCV positivity among control subjects; most were in the range of 2 to 3%. Taken as a whole, the evidence is strong that Taiwan Chinese patients with HCC and control subjects have different HCV profiles compared with their counterparts in the People's Republic of China. It is interesting to note that one distinguishing feature between Taiwan and mainland (i.e. People's Republic of China) Chinese is that the former had had considerably more contact with Japanese who ruled Taiwan between 1895 and 1945, and whose HCV profile (both in HCC patients and in the general population) is dissimilar from the mainland Chinese but quite similar to the Taiwan Chinese. Studies in Japan have reported anti-HCV positivity rates of 50-70% among HCC patients and 2-3% among control subjects (Ito et al., 1991; Tanaka et al., 1991; Nakashima et al., 1992; Tomimatsu et al., 1993; Hamasaki et al, 1993; Tanaka et al., 1994; Suga et al., 1994) .
There is some evidence that Chinese in Hong Kong, in terms of HCV profile, are quite similar to their counterparts in the People's Republic of China. Leung et al. (1992) noted an anti-HCV positivity rate of 7.3% (31/424) in patients with HCC (90% were men) and 0.6% (1/175) in control subjects. The anti-HCV assay used in this study was the first-493 generation ELISA manufactured by Ortho Diagnostic Systems. No independent confirmatory tests were performed on positive samples.
